A Phase 3, Multi-Center Study Evaluating PL9643 in Patients with Dry Eye
Trial details
- Registry ID
- NCT05201170
- Drugs studied
- PL9643 Ophthalmic Solution, Vehicle Ophthalmic Solution
TrialRedline tracks 5 clinical trials sponsored by Palatin Technologies, Inc: 1 Phase 3, 4 Phase 2.
Company identity checked against sources
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| A Phase 3, Multi-Center Study Evaluating PL9643 in Patients with Dry EyeNCT05201170 | PL9643 Ophthalmic Solution, Vehicle Ophthalmic Solution | Completed | 2023-09-01Actual |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Phase 2a to Evaluate PL-8177 in Subjects with Active Ulcerative Colitis (UC)NCT05466890 | PL8177 | Active not recruiting | 2025-02-10Actual |
| A Phase 2 Study Evaluating the Co-Administration of Bremelanotide With Tirzepatide for the Treatment of ObesityNCT06565611 | bremelanotide, tirzepatide | Active not recruiting | 2025-02-05Actual |
| A Phase IIb, Multicenter, Open-Label, Prospective Study of Bremelanotide in Diabetic Kidney DiseaseNCT05709444 | Bremelanotide, RAAS inhibition therapy | Completed | 2024-04-26Actual |
| Study to Evaluate Sex Differences in the Acute Effects of PL-3994 in Heart Failure SubjectsNCT04318145 | PL-3994 Aqueous Intravenous Solution Dose Ascention, PL-3994 Aqueous Intravenous Solution Single Dose | Terminated | 2023-12-08Actual |
Names as written in the registry records.
NCT04318145 · Palatin Technologies, Inc
Before: Estimated. After: Actual.
Before: 55 participants (planned). After: 15 participants (actual).
Before: Estimated. After: Actual.
Before: 31 Mar 2022. After: 8 Dec 2023.
Before: Recruiting. After: Terminated.